Documents Relied Upon
`
`ANALYST REPORTS
` “Global BioPharmaceuticals: Game Changes in Multiple Sclerosis,” Barclays, March 7,
`2014.
` “Global Biotechnology,” Credit Suisse, April 4, 2014.
` “Global Biotechnology and Pharmaceuticals – AAN 2014,” Credit Suisse, April 30,
`2014.
` “Multiple Sclerosis: It’s a Revolution! (vs. Evolution),” Credit Suisse, December 12,
`2013.
` “Spec Pharmaceuticals,” Morgan Stanley, March 3, 2014.
` “Teva,” Morgan Stanley, March 14, 2014.
` “Teva Pharmaceutical Industries Ltd. (TEVA),” Citi, February 2, 2014.
` “Teva Pharmaceutical Industries Ltd. (TEVA),” Citi, April 4, 2014.
`
`DRUG LABELS
` Aubagio® label, October 17, 2014.
` Avonex® label, August 28, 2014.
` Betaseron® label, September 25, 2015.
` Copaxone® label, January 28, 2014.
` Extavia® label, August, 14, 2009.
` Gilenya® label, August 4, 2015.
` Glatopa™ label, April 16, 2015.
` Lemtrada® label, November 14, 2014.
` Novantrone® label, March 23, 2012.
` Plegridy® label, August 15, 2014.
` Rebif® label, March 10, 2015.
` Tecfidera® label, December 3, 2014.
` Tysabri® label, May 12, 2015.
`
`
`EXPERT REPORTS AND DEPOSITIONS
`
`
` Declaration of Edward J. Fox, M.D., Ph.D. in Support of Patent Owner Yeda’s Response
`to Institution of Inter Parties Review filed on November 20, 2015.
` Deposition of Dr. Ari Green, October 22, 2015.
`
`IMS DATA
`
`IMS Data.
`
`
`INTERNAL DOCUMENTS
`
`
`
`
`
`
`
`Page 1 of 3
`
`YEDA EXHIBIT NO. 2106
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`
`
`
`
`
` 2015 MS Mid-Year Tracker, FINAL REPORT APPENDIX – SEPTEMBER 2015.
` TEVCOP00449084–115.
` TEVCOP00450191–93.
` TEVCOP00451650–52.
`
`
`OTHER PUBLICATIONS
` Berndt, E. R., et al., “An Analysis of the Diffusion of New Antidepressants: Variety,
`Quality, and Marketing Efforts,” The Journal of Mental Health Policy and Economics,
`2002, Vol. 5, No. 1, pp. 3–19.
` Cohen, J., et al., “Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A
`Randomized Clinical Trial,” JAMA Neurology, October 12, 2015.
` Donohue, J. M., et al., “A Decade of Direct-to-Consumer Advertising of Prescription
`Drugs,” The New England Journal of Medicine, 2007, Vol. 357, No. 7, pp. 573–681.
` Leffler, K. B., “Persuasion or Information? The Economics of Prescription Drug
`Advertising,” J.L. & Econ., 1981, Vol. 24, No. 1, pp. 45–74.
` Thomas, J. R., “Patent Infringement and Experimental Use Under the Hatch-Waxman
`Act: Current Issues,” Congressional Research Service, 2012.
` Venkataraman, S. and Stremersch, S., “The Debate on Influencing Doctors’ Decisions:
`Are Drug Characteristics the Missing Link?” Management Science, 2007, Vol. 53, No.
`11, pp. 1688–1701.
` Wynn D., et al., “Patient Experience with Glatiramer Acetate 40 mg/1 mL Three-Times
`Weekly Treatment for Relapsing-Remitting Multiple Sclerosis: Results from the
`GLACIER Extension Study,” The American Academy of Neurology 2015 Annual
`Meeting, Washington, D.C., April 18–25, 2015.
`
`
`PATENTS
` U.S. Patent No. 8,232,250.
` U.S. Patent No. 8,377,885.
` U.S. Patent No. 8,399,413.
` U.S. Patent No. 8,796,226.
` U.S. Patent No. 8,969,302.
`
`
`WEBSITES
` Biogen, “Above MS™ Program,” available at http://www.tecfidera.com/join-biogen-
`support/ (last visited on 11/12/2015).
` California State Board of Pharmacy, “2015 Lawbook for Pharmacy,” available at
`http://www.pharmacy.ca.gov/laws_regs/lawbook.pdf (last visited on 11/16/2015).
` Copaxone® website, available at www.copaxone.com (last visited on 11/12/2015).
` Copaxone® website, “3-TIMES-A-WEEK COPAXONE® 40 MG,” available at
`www.copaxone.com/about-copaxone/copaxone-40-mg (last visited on 11/12/2015).
`
`
`
`
`
`
`
`Page 2 of 3
`
`YEDA EXHIBIT NO. 2106
`MYLAN PHARM. v YEDA
`IPR2015-00644
`
`

`
`
`
`
`
`
`
`
`
`
`
`
` Copaxone® website, “COPAXONE® − A proven mix of efficacy, safety, and tolerability
`in relapsing forms of MS,” available at https://www.copaxonehcp.com/about-copaxone
`(last visited on 11/18/2015).
`IMS Health, “Our Company,” available at http://www.imshealth.com/en/about-us/our-
`company (last visited on 11/16/2015).
` National Multiple Sclerosis Society, “Definition of MS,” available at
`http://www.nationalmssociety.org/What-is-MS/Definition-of-MS (last visited on
`11/12/2015).
` National Multiple Sclerosis Society, “MS Symptoms,” available at
`http://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms (last visited on
`11/12/2015).
` National Multiple Sclerosis Society, “The MS Disease-Modifying Medications,” January
`2015, available at http://www.nationalmssociety.org/dmd (last visited on 11/12/2015).
` National Multiple Sclerosis Society, “Types of MS,” available at
`http://www.nationalmssociety.org/What-is-MS/Types-of-MS (last visited on
`11/12/2015).
` National Multiple Sclerosis Society, “What Is MS?” available at
`http://www.nationalmssociety.org/What-is-MS (last visited on 11/12/2015).
` Sandoz, “GlatopaCare™,” available at http://glatopa.com/glatopa_care/index.shtml (last
`visited on 11/12/2015).
` Sandoz, “GlatopaCare™: Co-Pay Program & Insurance and Benefits Investigation,”
`available at http://www.glatopa.com/glatopa_care/financial_support.shtml (last visited on
`11/12/2015).
` Teva, “Doctor Discussion Guide,” available at
`https://www.copaxone.com/Resources/pdfs/DoctorDiscussionGuide.pdf (last visited on
`11/12/2015).
` Teva, “Informed Treatment Decision Brochure,” available at
`https://www.copaxone.com/Resources/pdfs/Informed_Treatment_Decision_Brochure.pdf
`(last visited on 11/12/2015).
` Teva, “Shared Solutions®,” available at
`https://www.copaxone.com/Resources/pdfs/Shared_Solutions_Brochure.pdf (last visited
`on 11/12/2015).
`
`
`
`
`
`Page 3 of 3
`
`YEDA EXHIBIT NO. 2106
`MYLAN PHARM. v YEDA
`IPR2015-00644